Dyke, GB
Alan Dyke, Cambridgeshire GB
Patent application number | Description | Published |
---|---|---|
20140357903 | PROCESS FOR HYDROGENATING KETONES IN THE PRESENCE OF RU(II) CATALYSTS - The present invention relates to a process for hydrogenating a substrate including a carbon-heteroatom double bond, the process including the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst is a complex of formula (I): | 12-04-2014 |
Alan Dyke, London GB
Patent application number | Description | Published |
---|---|---|
20100240898 | CHIRAL PHOSPHORUS COMPOUND - The present invention relates to novel chiral phosphorus compounds which can be readily prepared from quinoline derivatives as inexpensive starting compounds and have the general formula (I) wherein R | 09-23-2010 |
20120004411 | CHIRAL PHOSPHORUS COMPOUND - The present invention relates to novel chiral phosphorus compounds which can be readily prepared from quinoline derivatives as inexpensive starting compounds and have the general formula (I) wherein R | 01-05-2012 |
20120264940 | CHIRAL PHOSPHORUS COMPOUND - The present invention relates to novel chiral phosphorus compounds which can be readily prepared from quinoline derivatives as inexpensive starting compounds and have the general formula (I) | 10-18-2012 |
20130150583 | CHIRAL PHOSPHORUS COMPOUND - Methods of making a chiral phosphorus compound of formula (X) are disclosed: | 06-13-2013 |
Alan Dyke, Southampton GB
Patent application number | Description | Published |
---|---|---|
20100184998 | ORGANIC COMPOUNDS - The present invention relates to olefin metathesis processes for the manufacture of a compound of the formula (I) | 07-22-2010 |
Alan Dyke, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20120123142 | PROCESS FOR HYDROGENATING KETONES IN THE PRESENCE OF RU(II) CATALYSTS - The present invention relates to a process for hydrogenating a substrate comprising a carbon-heteroatom double bond, the process comprising the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydrogenation catalyst is a complex of formula (I): R | 05-17-2012 |
Alan Malcolm Dyke, Cambridge GB
Patent application number | Description | Published |
---|---|---|
20110295008 | PROCESS FOR PREPARING CATIONIC RUTHENIUM COMPLEXES - A process is described for the preparation of a solid cationic [ruthenium (arene) (phosphorus ligand) (halogen)] complex comprising the step of treating the complex with at least one alkane. Further described is a process for preparing a cationic [ruthenium (arene) {4,4′-bis(disubstituted-phosphino)-3,3′-bipyridine} (halogen)] complex comprising the step of reacting [ruthenium (arene) (halogen) 2]2 and a 4,4′-bis(disubstituted-phosphino)-3,3′-bipyridine ligand in a solvent consisting of at least one alcohol. | 12-01-2011 |
Amy Elizabeth Dyke, Bristol, South Gloucestershire GB
Patent application number | Description | Published |
---|---|---|
20150354131 | FERROMAGNETIC FIBRE COMPOSITES - The invention relates to ferromagnetic fibre composites, particularly ferromagnetic coated fibre plies in fibre reinforced polymer composites (FRPC), more preferably to a ferromagnetic FRPC, and composites with a plurality of functionalised fibre layers. | 12-10-2015 |
Amy Elizabeth Dyke, Bristol GB
Patent application number | Description | Published |
---|---|---|
20110111266 | ELECTRICAL POWER SOURCES - An electrical power source including at least one hollow fibre incorporated in a material structure, wherein the at least one hollow fibre forms part of an electric circuit capable of storing or generating electrical power. In this way power sources may be provided as an integral part of a fibre composite structure or fabric. | 05-12-2011 |
20130059173 | COMPONENT INCLUDING A RECHARGEABLE BATTERY - A component is disclosed which includes a rechargeable battery, and a method is also disclosed of producing such a component. The component can use lithium ion chemistry and the battery can have an anode structure, a cathode structure, and a separator structure which separates the anode from the cathode and contains an electrolyte. The anode structure and the cathode structure can each be formed from a composite material which includes electrically conductive fibres and electrochemically active material in a binder matrix, and the battery can be formed to be structurally inseparable from the rest of the component. | 03-07-2013 |
20150044572 | ELECTRICAL ENERGY STORAGE STRUCTURES - According to the invention there is provided a structural metallic rechargeable battery and a method of producing same. The battery uses one of an acid, alkaline or Li-ion chemistry and the battery has an anode structure, a cathode structure, each of which comprise a conductive foam which contains the active electrochemical reagents, and a structural separator which separates the conductive foams of anode from the cathode respectively. The anode structure and the cathode structure are each formed from a metal sheet or foil. | 02-12-2015 |
Amy Elizabeth Dyke, South Gloucestershire GB
Patent application number | Description | Published |
---|---|---|
20140120422 | COMPONENT INCLUDING A RECHARGEABLE BATTERY - According to the invention there is provided a component including a rechargeable battery and a method of producing same. The component uses one of an acid and an alkaline chemistry and the battery has an anode structure, a cathode structure, and a separator structure which separates the anode from the cathode and contains an electrolyte. The anode structure and the cathode structure are each formed from a composite material which includes electrically conductive fibres and electrochemically active material in a binder matrix including less than 50% w/w of an elastomer binder and the battery is formed to be structurally inseparable from the rest of the component. | 05-01-2014 |
20140311329 | PROTECTIVE MATERIAL - According to the invention there is provided a protective material for dissipating the kinetic energy of a moving object including a plurality of layers of fibrous armour material in which at least some adjacent layers of fibrous armour material are separated by one or more separator layers for reducing inter-layer friction. | 10-23-2014 |
Amy Elizabeth Dyke, Aust GB
Patent application number | Description | Published |
---|---|---|
20120308887 | RECHARGEABLE BATTERIES - A rechargeable battery is disclosed having electrode and separator structures which are made up of fibre-reinforced composite material, thereby allowing the battery itself to serve as an integral structural component. The utilisation or efficiency of the rechargeable battery is considerably enhanced by rendering at least part of the matrix material of the electrodes and the separator porous, thereby to facilitate improved access to active sites on the electrodes, with the porosity in the separator allowing improved ion transport, both of which enhance cell operation. The porous structure also provides improved electrolyte containment and retention in the event of damage. | 12-06-2012 |
20120314337 | ELECTROSTATIC CAPACITOR DEVICE - An electrostatic capacitor device is disclosed including first and second spaced apart electrode structures separated by a dielectric structure in which the first and second electrode structures are each formed from a composite material which includes electrically conductive fibres in a binder matrix. | 12-13-2012 |
20140126108 | HIGH ENERGY CAPACITORS - The following invention relates to high energy capacitors with increased thermal resilience over conventional bulk ceramic capacitors, particularly capacitors that may be formed into a three dimensional shape to fit inside an existing device. The capacitor is provided with first and second electrodes which have a plurality of interlocating protrusions, which increase the relative surface area of the electrodes. The first and second electrodes and interlocating protrusions are provided with through holes. The devices are filled with a flowable dielectric material. | 05-08-2014 |
Hazel Dyke, Essex GB
Patent application number | Description | Published |
---|---|---|
20080269239 | Pyrimidine Compounds as Histamine Modulators - The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds. | 10-30-2008 |
Hazel Dyke, Harlow GB
Patent application number | Description | Published |
---|---|---|
20080261946 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders - The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds. | 10-23-2008 |
Hazel Ann Dyke, Aust GB
Patent application number | Description | Published |
---|---|---|
20120314337 | ELECTROSTATIC CAPACITOR DEVICE - An electrostatic capacitor device is disclosed including first and second spaced apart electrode structures separated by a dielectric structure in which the first and second electrode structures are each formed from a composite material which includes electrically conductive fibres in a binder matrix. | 12-13-2012 |
20140126108 | HIGH ENERGY CAPACITORS - The following invention relates to high energy capacitors with increased thermal resilience over conventional bulk ceramic capacitors, particularly capacitors that may be formed into a three dimensional shape to fit inside an existing device. The capacitor is provided with first and second electrodes which have a plurality of interlocating protrusions, which increase the relative surface area of the electrodes. The first and second electrodes and interlocating protrusions are provided with through holes. The devices are filled with a flowable dielectric material. | 05-08-2014 |
Hazel Anne Dyke, Bristol, South Gloucestershire GB
Patent application number | Description | Published |
---|---|---|
20150354131 | FERROMAGNETIC FIBRE COMPOSITES - The invention relates to ferromagnetic fibre composites, particularly ferromagnetic coated fibre plies in fibre reinforced polymer composites (FRPC), more preferably to a ferromagnetic FRPC, and composites with a plurality of functionalised fibre layers. | 12-10-2015 |
Hazel Anne Dyke, Aust GB
Patent application number | Description | Published |
---|---|---|
20130312535 | STRUCTURAL HEALTH MONITORING USING SPRAYABLE PAINT FORMULATIONS - The structural health of a structure such as an aircraft is monitored by spraying a paint formulation containing a loading of carbon nanoparticles to provide a paint layer forming part of a paint system. The paint layer forms a smart skin whose electrical properties may be monitored to determine structural health. | 11-28-2013 |
Hazel J. Dyke, Harlow GB
Patent application number | Description | Published |
---|---|---|
20130053364 | Sulphone Compounds and Methods of Making and Using Same - The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 02-28-2013 |
20140378462 | TRICYCLIC SULFONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 12-25-2014 |
20150119456 | TRICYCLIC SULFONE COMPOUNDS AND METHODS OF MAKING AND USING SAME - The invention provides tricyclic sulfone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 04-30-2015 |
Hazel Joan Dyke, Harlow GB
Patent application number | Description | Published |
---|---|---|
20080242655 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE - The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 10-02-2008 |
20110118230 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-19-2011 |
20110124654 | DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 05-26-2011 |
20120172393 | (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 07-05-2012 |
20120238541 | PHARMACEUTICAL COMPOUNDS - The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer. | 09-20-2012 |
20130012545 | Amido-Thiophene Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 01-10-2013 |
20130123235 | Tricyclic Compounds and Methods of Making and Using Same - The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 05-16-2013 |
20130217759 | Sulphonamine Compounds and Methods of Making and Using Same - The invention provides sulphonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 08-22-2013 |
20130331420 | TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME - Described herein are tetrazole compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tetrazole compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 12-12-2013 |
20140073623 | Tricyclic Sulfonamide Compounds and Methods of Making and Using Same - The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 03-13-2014 |
20140080822 | Tricyclic Pyrazole Sulphonamide Compounds and Methods of Making and Using Same - The invention provides tricyclic sulfonamide compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 03-20-2014 |
20140088078 | Partially Saturated Tricyclic Compounds and Methods of Making and Using Same - The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 03-27-2014 |
20140171407 | 1,7-DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 06-19-2014 |
20150087630 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER - Methods of use of compounds of formula (I) for treating cancer: | 03-26-2015 |
20150328195 | 1,7-DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 11-19-2015 |
Hazel Joan Dyke, Storrington GB
Patent application number | Description | Published |
---|---|---|
20110183938 | 1,7-DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 07-28-2011 |
20110201593 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - The invention provides novel compounds of formula I having the general formula: | 08-18-2011 |
20130123268 | 3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIO- PHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, 3,3-disubstituted-(6-aza-bicyclo[3.1.1]hept-6-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, and 4,4-disubstituted piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds of the following formula that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 05-16-2013 |
Hazel Joan Dyke, Essex GB
Patent application number | Description | Published |
---|---|---|
20090137622 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula I | 05-28-2009 |
20100216768 | N-SUBSTITUTED AZAINDOLES AND METHODS OF USE - The invention relates to N-substituted azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to N-substituted azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 08-26-2010 |
20100267696 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 10-21-2010 |
20100305065 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula wherein R | 12-02-2010 |
20110015178 | Amido-Thiophene Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 01-20-2011 |
20120095046 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 04-19-2012 |
20120231995 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula I | 09-13-2012 |
Kevin J. Dyke, Staffordshire GB
Patent application number | Description | Published |
---|---|---|
20150357941 | VOLTAGE SOURCE CONVERTER COMPRISING A CHAIN-LINK CONVERTER - A voltage source converter comprises: at least two converter limbs, each converter limb extending between DC terminals and having limb portions separated by an AC terminal. Each limb portion includes at least one switching element and at least one chain-link converter including series-connected modules. Each module includes at least one switching element and at least one energy storage device that combine to selectively provide a voltage source. The chain-link converter(s) form a branch to interconnect two AC terminals. Each limb portion is switchable to switch the corresponding chain-link converter(s) into and out of circuit with a respective DC terminal. The chain-link converter(s) is switchable to control the configuration of an AC voltage at each corresponding AC terminal. The converter further includes a control unit that coordinates the switching of the limb portions and the chain-link converter(s) to cause transfer of real power between the AC and DC electrical networks. | 12-10-2015 |
Kevin J. Dyke, Stafford GB
Patent application number | Description | Published |
---|---|---|
20150035364 | CONTROL CIRCUIT - A control circuit ( | 02-05-2015 |
20150349536 | CONTROL CIRCUIT - A control circuit ( | 12-03-2015 |
20150357901 | VOLTAGE SOURCE CONVERTER - A voltage source converter includes a converter limb extending between DC terminals and having limb portions separated by an AC terminal, the DC terminals being connectable to a DC electrical network and the AC terminal being connectable to an AC electrical network. Each limb portion includes at least one switching element and a chain-link converter including a series-connected modules, each module including at least one switching element and at least one energy storage device combining to selectively provide a voltage source. The chain-link converter is connected to the AC terminal, and the switching element(s) of each limb portion is switchable to switch the chain-link converter into and out of circuit with the corresponding DC terminal. The voltage source includes a control unit which coordinates the switching of the switching elements of the limb portions and the switching element(s) in each module of the chain-link converter. | 12-10-2015 |
20150357931 | CONVERTER - A voltage source converter ( | 12-10-2015 |
Simon Dyke, Southampton GB
Patent application number | Description | Published |
---|---|---|
20140168277 | Adaptive Presentation of Content - A method of operating a client device within a viewing environment is described. The method includes: receiving content at a client device, presenting the content to a viewer by rendering the content as rendered content on a display surface in operable communication with the client device; receiving engagement data at the client device, the engagement data indicating a level of engagement with the content of at least one user who is viewing the rendered content; and adapting presentation of the content in dependence on the engagement data by changing how the content is rendered on the display surface. Related systems, apparatus, and methods are also described. | 06-19-2014 |
Simon Dyke, Southampton Hampshire GB
Patent application number | Description | Published |
---|---|---|
20120246671 | DETECTING PERIODIC ACTIVITY PATTERNS - A method of detecting periodic activity patterns associated with the viewing of audio video content is described. The method includes: recording activity data in an activity log; suppressing the activity log one or more times to suppress non-relevant activity data thereby producing one or more sets of suppressed activity data; passing the one or more sets of suppressed activity data through a signal processing function to convert the one or more sets of suppressed activity data to one or more frequency responses; and analysing the one or more frequency responses to detect the periodic activity patterns. Related apparatus and methods are also described. | 09-27-2012 |
Simon Dyke, Hampshire GB
Patent application number | Description | Published |
---|---|---|
20120072282 | ADVERTISEMENT SELECTION - An end-user rendering system including an advertisement database to receive advertisements, and store the advertisements therein, a state database to store information, a decision model optimization module to receive a tree-type decision model and optimize the tree-type decision model based on at least some of the information stored in the state database, an advertisement decision module to evaluate the optimized tree-type decision model and select an advertising campaign, the selected advertising campaign having at least one advertisement, and a rendering module to render the at least one advertisement of the selected advertising campaign. Related apparatus and methods are also described. | 03-22-2012 |
20130061256 | USER PRESENCE CONFIDENCE AND MEDIA CONTENT VIEWING ESTIMATION - A content viewing estimation system including a module to receive a time measurement of how long at least part of a content item was rendered by an end-user rendering unit and outputted for display to an audio-visual outputting arrangement during a time window, a module to determine user interaction with the end-user rendering unit and/or the audio-visual outputting arrangement, a module to calculate an average content item duration of a plurality of content items rendered by the end-user rendering unit during the time window, and a module to estimate viewing by the user of the at least part content item such that if user interaction was not determined during the time window then time attributed to the viewing of the at least part content item is set to the minimum of a capping limit, the time measurement, and the average content item duration. Related apparatus and methods are also described. | 03-07-2013 |